Economic Analyses of the REDUCE Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01337258|
Recruitment Status : Completed
First Posted : April 18, 2011
Last Update Posted : May 30, 2017
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment.
The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.
|Condition or disease||Intervention/treatment|
|Neoplasms, Prostate Benign Prostatic Hyperplasia Cancer||Drug: Dutasteride Drug: Placebo|
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Official Title:||Economic Analyses Alongside the REDUCE Clinical Trial|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||July 2010|
|Men at increased risk for Prostate Cancer (PCA)||
dutasteride 0.5mg daily.
Other Name: Placebo
Men taking placebo daily
- Cost of treating prostate-related events [ Time Frame: REDUCE clinical trial, 4 year time period ]Prostate Related Events include Benign Prostatic Hyperplasia (BPH), Prostate Cancer (PCA) and Prostatitis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01337258
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|